These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27159879)

  • 41. Delivery strategies to enhance mucosal vaccination.
    Chadwick S; Kriegel C; Amiji M
    Expert Opin Biol Ther; 2009 Apr; 9(4):427-40. PubMed ID: 19344280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivery systems and adjuvants for oral vaccines.
    Lavelle EC; O'Hagan DT
    Expert Opin Drug Deliv; 2006 Nov; 3(6):747-62. PubMed ID: 17076597
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Delivery systems: a vaccine strategy for overcoming mucosal tolerance?
    Mann JF; Acevedo R; Campo JD; Pérez O; Ferro VA
    Expert Rev Vaccines; 2009 Jan; 8(1):103-12. PubMed ID: 19093777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
    Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
    Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dry powder vaccines for mucosal administration: critical factors in manufacture and delivery.
    Wang SH; Thompson AL; Hickey AJ; Staats HF
    Curr Top Microbiol Immunol; 2012; 354():121-56. PubMed ID: 21822816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulators and delivery systems for vaccination by mucosal routes.
    Ryan EJ; Daly LM; Mills KH
    Trends Biotechnol; 2001 Aug; 19(8):293-304. PubMed ID: 11451471
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Particulate formulations for the delivery of poly(I:C) as vaccine adjuvant.
    Hafner AM; Corthésy B; Merkle HP
    Adv Drug Deliv Rev; 2013 Oct; 65(10):1386-99. PubMed ID: 23751781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phospholipid bilayer-coated aluminum nanoparticles as an effective vaccine adjuvant-delivery system.
    Wang T; Zhen Y; Ma X; Wei B; Wang N
    ACS Appl Mater Interfaces; 2015 Apr; 7(12):6391-6. PubMed ID: 25780860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Advances and challenges in mucosal adjuvant technology.
    Newsted D; Fallahi F; Golshani A; Azizi A
    Vaccine; 2015 May; 33(21):2399-405. PubMed ID: 25865473
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
    Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Delivery strategies to enhance oral vaccination against enteric infections.
    Davitt CJ; Lavelle EC
    Adv Drug Deliv Rev; 2015 Aug; 91():52-69. PubMed ID: 25817337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mass vaccination: solutions in the skin.
    Glenn GM; Kenney RT
    Curr Top Microbiol Immunol; 2006; 304():247-68. PubMed ID: 16989274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quillaja saponaria extract as mucosal adjuvant with chitosan functionalized gold nanoparticles for mucosal vaccine delivery: stability and immunoefficiency studies.
    Barhate G; Gautam M; Gairola S; Jadhav S; Pokharkar V
    Int J Pharm; 2013 Jan; 441(1-2):636-42. PubMed ID: 23117021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel approaches to vaccine delivery.
    O'Hagan DT; Rappuoli R
    Pharm Res; 2004 Sep; 21(9):1519-30. PubMed ID: 15497674
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin.
    Glenn GM; Kenney RT; Ellingsworth LR; Frech SA; Hammond SA; Zoeteweij JP
    Expert Rev Vaccines; 2003 Apr; 2(2):253-67. PubMed ID: 12899576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK; Aldwell FE; Beagley KW
    Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.